HERM ROSENMAN
CIK 1230057 · Chief Financial Officer · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.36M
Companies
7
Total Filings
109
Lifetime Open-Market Net
-$31.22M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NTRA | Director | 4,250 | $320.76 | $1.36M | -$28.40M | 48 | 2026-06-26 |
| DermTech, Inc. (DMTK) Delisted | Director | 134,576 | $0.09 | $12.7K | $274.6K | 8 | 2023-06-05 |
| Oxford Immunotec Global PLC (OXFD) Delisted | Director | 4,081 | — | — | $0 | 7 | 2020-06-26 |
| VIVUS INC (VVUS) Delisted | Director | 36,168 | — | — | $159.0K | 21 | 2020-02-24 |
| GPRO | Senior VP, Finance & CFO | 0 | $1.23 | $0 | -$3.25M | 17 | 2012-08-02 |
| ARYx Therapeutics, Inc. (ARYX) Delisted | Director | — | — | — | $0 | 3 | 2010-05-03 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Director | — | $0.04 | — | $0 | 1 | 2007-09-14 |
Recent Filings · Page 4 of 11
109 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-27 | NTRA | Exer (M) | +1,307 | $0 | EDGAR |
| 2022-05-11 | DermTech, Inc. (DMTK) Delisted | Buy (P) | +20,000 | $137.3K | EDGAR |
| 2021-11-09 | NTRA | Mixed | — | -$5.11M | EDGAR |
| 2021-11-09 | NTRA | Mixed | — | -$1.19M | EDGAR |
| 2021-06-02 | NTRA | Mixed | +2,856 | $0 | EDGAR |
| 2021-05-28 | DermTech, Inc. (DMTK) Delisted | Grant (A) | +9,158 | $0 | EDGAR |
| 2021-03-12 | — | Disp (D) | −4,081 | -$89.8K | |
| 2020-06-26 | Oxford Immunotec Global PLC (OXFD) Delisted | Grant (A) | +4,081 | $0 | EDGAR |
| 2020-06-19 | DermTech, Inc. (DMTK) Delisted | Grant (A) | +8,000 | $0 | EDGAR |
| 2020-06-16 | NTRA | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.